Value
6.9/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 6.1 |
| Analyst target | 7.5 |
ENTA · Why this verdict
Why Enanta Pharmaceuticals (ENTA) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.8/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Enanta is free-cash-flow positive despite reporting a GAAP loss, with an FCF margin of 11% and FCF yield of 1.7%. Quality breakdown | FCF margin should hold steady or improve as the company's revenue base grows. | →Stable |
| CounterA thin 1.7% FCF yield leaves little cushion, and any working-capital swing could turn FCF negative again. | ||
Enanta has beaten earnings estimates in all of the last four quarters, with the engine highlighting both the beat streak and positive momentum as bullish factors. Bull case | The beat streak should continue into the next reported quarter. | →Stable |
| CounterA perfect beat streak raises the bar for consensus estimates, making the next beat progressively harder to achieve. | ||
The bear case flags a leverage penalty from a 1.6 debt-to-equity ratio alongside negative news sentiment of -0.67. Bear case | News sentiment should turn positive and the leverage penalty should ease as debt is paid down or earnings grow into it. | →Stable |
| CounterFor a biotech nearing commercialization, temporary negative news sentiment often reflects short-term clinical or regulatory noise rather than a durable deterioration. | ||
The engine's asymmetry gate has failed at the current spot price, with the 1.07 risk/reward ratio falling short of the 1.5 threshold required. Warnings | The asymmetry ratio should climb above 1.5 as either the price pulls back to a better entry or the target is raised. | →Stable |
| CounterA narrow miss on the asymmetry threshold, 1.07 versus 1.5, is a marginal signal that could flip with small changes in price or target. | ||
The stock is overbought with an RSI of 81 while trading above its 200-day moving average and showing rising on-balance volume. Momentum breakdown | RSI should cool toward the 40-60 neutral range without a sharp price decline. | →Stable |
| CounterStrong momentum names in biotech can remain overbought for extended periods heading into a binary catalyst like an earnings report. | ||
Enanta is free-cash-flow positive despite reporting a GAAP loss, with an FCF margin of 11% and FCF yield of 1.7%.
→StableQuality breakdown
- Expectation
- FCF margin should hold steady or improve as the company's revenue base grows.
CounterA thin 1.7% FCF yield leaves little cushion, and any working-capital swing could turn FCF negative again.
Enanta has beaten earnings estimates in all of the last four quarters, with the engine highlighting both the beat streak and positive momentum as bullish factors.
→StableBull case
- Expectation
- The beat streak should continue into the next reported quarter.
CounterA perfect beat streak raises the bar for consensus estimates, making the next beat progressively harder to achieve.
The bear case flags a leverage penalty from a 1.6 debt-to-equity ratio alongside negative news sentiment of -0.67.
→StableBear case
- Expectation
- News sentiment should turn positive and the leverage penalty should ease as debt is paid down or earnings grow into it.
CounterFor a biotech nearing commercialization, temporary negative news sentiment often reflects short-term clinical or regulatory noise rather than a durable deterioration.
The engine's asymmetry gate has failed at the current spot price, with the 1.07 risk/reward ratio falling short of the 1.5 threshold required.
→StableWarnings
- Expectation
- The asymmetry ratio should climb above 1.5 as either the price pulls back to a better entry or the target is raised.
CounterA narrow miss on the asymmetry threshold, 1.07 versus 1.5, is a marginal signal that could flip with small changes in price or target.
The stock is overbought with an RSI of 81 while trading above its 200-day moving average and showing rising on-balance volume.
→StableMomentum breakdown
- Expectation
- RSI should cool toward the 40-60 neutral range without a sharp price decline.
CounterStrong momentum names in biotech can remain overbought for extended periods heading into a binary catalyst like an earnings report.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Enanta Pharmaceuticals combines a perfect earnings beat streak and positive momentum with leverage concerns, negative news sentiment, and a narrow miss on the engine's risk/reward gate.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 9.2 |
| FCF quality | 5.2 |
| Moat | 5.8 |
| Rule of 40 | 5.5 |
| Piotroski F | 4.4 |
- ▸FCF-positive despite GAAP loss (FCF margin 11%, FCF yield 1.8%)
Growth
6.2/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 6.2 |
Momentum
5.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.4 |
| MACD | 9.8 |
| OBV | 4.4 |
| MA position | 9.0 |
| Volume | 1.7 |
- ▸Overbought (RSI 73)
- ▸Above 200-day MA
Sentiment
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.0 |
| Analyst rating | 7.7 |
| Price target | 9.1 |
- ▸Light analyst coverage (7.0) — signal dampened
- ▸Analyst upside: 39%
Insider
7.5/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
3.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 6.9 |
| quality rank | 1.2 |
| growth rank | 5.1 |
Technical
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.7 |
| support resistance | 2.3 |
| 52w position | 6.9 |
| gap | 6.0 |
Risk (lower is worse)
4.2/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 5.0 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 1.0 |
| max pain risk | 7.0 |
| beta | 7.2 |
| debt equity | 3.8 |
- ▸High IV: 74%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 5.0 |
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (7)
- MOMENTUM:5.9>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:34d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:1.4<1.5@spot
Warning (0)
none
Reward-to-Risk
1.40
Upside
+20.9%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The F-path SELL output reflects an overall score of 4.8 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Sentiment at 7.6) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:1.4<1.5@spot) reinforce the read. Current asymmetry R:R is 1.40 — supplementary context, not the trigger for this path.
The strongest dimensions are Sentiment at 7.6, Insider at 7.5, and Catalyst at 7.0; the weakest are Peer rank at 3.5, Quality at 4.0, and Risk (lower is worse) at 4.2. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 1.40 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Perfect Earnings Beat Streak
Trip ifThe company's surprise_pct falls below 0% at its next earnings report.
- P2Leverage Penalty Negative Sentiment
Trip ifNews sentiment score stays below -0.5 for 2 more consecutive updates.
- P3Asymmetry Gate Failure At Spot
Trip ifAsymmetry ratio stays below 1.5 for 2 more consecutive engine runs.
- P4Overbought Momentum
Trip ifRSI stays above 80 for 2 more consecutive weeks.
- P5Fcf Positive Despite Gaap Loss
Trip ifFCF margin falls below 5% at the next reported quarter.